# Aperture Venture Partners

> Aperture Venture Partners is a VC fund backing Health Care and Biotechnology. See 65 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 65
- Last investment: Jul 2025
- Lead investor: 8%
- Fund size: $49M
- Last fund: Dec 2014
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/aperture-venture-partners/about/
- Website: http://www.aperturevp.com

Aperture Venture Partners is a venture capital group committed to working with exceptional entrepreneurs to tackle significant problems and create major new opportunities. They work with companies across a variety of sectors, primarily within the healthcare and healthy living industries. Their initial investment size ranges between $1 million and$5 million and they invest nationally. Their principals have been entrepreneurial leaders in the healthcare and investment industries over the past 30 years. They have successfully invested more than $1 billion and founded companies that have had combined revenues greater than $1 billion.

## Contacts

5 contacts available for Aperture Venture Partners. Shizune tracks 4 team members at Aperture Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/aperture-venture-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 34 | 52% |
| Biotechnology | 24 | 37% |
| Medical | 19 | 29% |
| Medical Device | 19 | 29% |
| Pharmaceutical | 9 | 14% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 16 | 25% |
| Series B | 13 | 20% |
| Series A | 8 | 12% |
| Series D | 7 | 11% |
| Funding Round | 6 | 9% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 39 | 60% |
| Israel | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Eric H. Sillman | Co-Founder | 2 | https://shizune.co/investors/profile/eric-h-sillman |
| Paul E. Tierney | Partner | 0 | https://shizune.co/investors/profile/paul-e-tierney-jr |
| Thomas Cooper | Senior Partner | 0 | https://shizune.co/investors/profile/thomas-cooper |
| Tony Natale | Managing Partner | 6 | https://shizune.co/investors/profile/tony-natale |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neuros Medical | Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $56M | Series D | Jul 09, 2025 |  |
| Shoulder Innovations | Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leveragesthis technology to create simple surgical instrumentation, which reduces operative time and cost.Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery. | $40M | Series E | Mar 10, 2025 |  |
| ShiraTronics | ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device acceleratorcompany. | $66M | Series B | Sep 30, 2024 |  |
| XII Medical | XII Medical is a medical device developer company. It develops a minimally invasive outpatient technology for the treatment of obstructive sleep apnea. | $45M | Series B | Aug 21, 2024 |  |
| Miach Orthopaedics | Miach Orthopaedics is a medical device company that develops bio-engineered surgical implants to facilitate new tissue growth. The company's product is the Bridge-Enhanced ACL Repair technology as a viable alternative to conventional ACL reconstruction for patients who have withstand an anterior cruciate ligament injury.Miach Orthopaedicswas founded on 2016 and is headquartered in Westborough, Massachusetts. | $20M | Series B | Apr 02, 2024 |  |
| Nalu Medical | Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California. | $85M | Series E | Jan 03, 2024 |  |
| Cortica | Cortica is a rapidly growing healthcare company pioneering a unique and effective approach to treating neurodevelopmental conditions including autism spectrum disorder, speech and language delays, sensory processing disorder and other conditions that impact brain development. Harnessing insights and technologies from emerging neuroscience, Corticabrings together clinical specialists from a range of disciplines to design and deliver comprehensive care to children with developmental differences. | $75M | Series D | Apr 17, 2023 |  |
| Shoulder Innovations | Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leveragesthis technology to create simple surgical instrumentation, which reduces operative time and cost.Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery. | $42M | Series D | Mar 06, 2023 |  |
| Serpex Medical | Serpex Medical develops steerable transbronchial tools that enable articulation and access to peripheral lung nodules in the airway and in the parenchyma. |  | Venture - Series Unknown | Jan 01, 2023 |  |
| XII Medical | XII Medical is a medical device developer company. It develops a minimally invasive outpatient technology for the treatment of obstructive sleep apnea. | $30M | Series A | May 05, 2022 |  |

10 of 65 investments shown.

## Co-investors
- [U.S. Venture Partners](https://shizune.co/investors/profile/us-venture-partners) — VC Fund, 8 deals together
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 6 deals together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 6 deals together
- [Third Point Ventures](https://shizune.co/investors/profile/third-point-ventures) — VC Fund, 6 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 6 deals together
- [Ajax Health](https://shizune.co/investors/profile/ajax-health) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Aperture Venture Partners invest in?

Aperture Venture Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series B stage. Most of the 65 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Aperture Venture Partners?

Public channels for Aperture Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Aperture Venture Partners?

The team at Aperture Venture Partners includes Eric H. Sillman (Co-Founder), Paul E. Tierney (Partner) and Thomas Cooper (Senior Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co